Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

医学 拉帕蒂尼 卡培他滨 曲妥珠单抗 紫杉烷 曲妥珠单抗 内科学 肿瘤科 中期分析 帕妥珠单抗 转移性乳腺癌 人口 乳腺癌 癌症 临床试验 结直肠癌 环境卫生
作者
Veronique C Dieras,David W. Miles,Sunil Verma,Mark Daniel Pegram,Manfred Welslau,Jose M Baselga,Ian E. Krop,Kim Blackwell,Silke Hoersch,Jin Xu,Marjorie Green,Luca Gianni
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:18 (6): 732-742 被引量:685
标识
DOI:10.1016/s1470-2045(17)30312-1
摘要

The antibody-drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane. Approval of this drug was based on progression-free survival and interim overall survival data from the phase 3 EMILIA study. In this report, we present a descriptive analysis of the final overall survival data from that trial.EMILIA was a randomised, international, open-label, phase 3 study of men and women aged 18 years or older with HER2-positive unresectable, locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane. Enrolled patients were randomly assigned (1:1) via a hierarchical, dynamic randomisation scheme and an interactive voice response system to trastuzumab emtansine (3·6 mg/kg intravenously every 3 weeks) or control (capecitabine 1000 mg/m2 self-administered orally twice daily on days 1-14 on each 21-day cycle, plus lapatinib 1250 mg orally once daily on days 1-21). Randomisation was stratified by world region (USA vs western Europe vs or other), number of previous chemotherapy regimens for unresectable, locally advanced, or metastatic disease (0 or 1 vs >1), and disease involvement (visceral vs non-visceral). The coprimary efficacy endpoints were progression-free survival (per independent review committee assessment) and overall survival. Efficacy was analysed in the intention-to-treat population; safety was analysed in all patients who received at least one dose of study treatment, with patients analysed according to the treatment actually received. On May 30, 2012, the study protocol was amended to allow crossover from control to trastuzumab emtansine after the second interim overall survival analysis crossed the prespecified overall survival efficacy boundary. This study is registered with ClinicalTrials.gov, number NCT00829166.Between Feb 23, 2009, and Oct 13, 2011, 991 eligible patients were enrolled and randomly assigned to either trastuzumab emtansine (n=495) or capecitabine and lapatinib (control; n=496). In this final descriptive analysis, median overall survival was longer with trastuzumab emtansine than with control (29·9 months [95% CI 26·3-34·1] vs 25·9 months [95% CI 22·7-28·3]; hazard ratio 0·75 [95% CI 0·64-0·88]). 136 (27%) of 496 patients crossed over from control to trastuzumab emtansine after the second interim overall survival analysis (median follow-up duration 24·1 months [IQR 19·5-26·1]). Of those patients originally randomly assigned to trastuzumab emtansine, 254 (51%) of 495 received capecitabine and 241 [49%] of 495 received lapatinib (separately or in combination) after study drug discontinuation. In the safety population (488 patients treated with capecitabine plus lapatinib, 490 patients treated with trastuzumab emtansine), fewer grade 3 or worse adverse events occurred with trastuzumab emtansine (233 [48%] of 490) than with capecitabine plus lapatinib control treatment (291 [60%] of 488). In the control group, the most frequently reported grade 3 or worse adverse events were diarrhoea (103 [21%] of 488 patients) followed by palmar-plantar erythrodysaesthesia syndrome (87 [18%]), and vomiting (24 [5%]). The safety profile of trastuzumab emtansine was similar to that reported previously; the most frequently reported grade 3 or worse adverse events in the trastuzumab emtansine group were thrombocytopenia (70 [14%] of 490), increased aspartate aminotransferase levels (22 [5%]), and anaemia (19 [4%]). Nine patients died from adverse events; five of these deaths were judged to be related to treatment (two in the control group [coronary artery disease and multiorgan failure] and three in the trastuzumab emtansine group [metabolic encephalopathy, neutropenic sepsis, and acute myeloid leukaemia]).This descriptive analysis of final overall survival in the EMILIA trial shows that trastuzumab emtansine improved overall survival in patients with previously treated HER2-positive metastatic breast cancer even in the presence of crossover treatment. The safety profile was similar to that reported in previous analyses, reaffirming trastuzumab emtansine as an efficacious and tolerable treatment in this patient population.F Hoffmann-La Roche/Genentech.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
朴素豪完成签到,获得积分10
1秒前
99发布了新的文献求助30
1秒前
2秒前
榴下晨光发布了新的文献求助10
2秒前
大_pan完成签到,获得积分10
3秒前
4秒前
4秒前
溺爱王楚钦完成签到,获得积分10
4秒前
淡淡代珊完成签到,获得积分10
4秒前
NexusExplorer的应助被尊敬鸿采纳,获得10
5秒前
5秒前
Joaquin完成签到,获得积分10
5秒前
王者归来完成签到,获得积分10
7秒前
7秒前
小y发布了新的文献求助10
7秒前
浮星凡羽发布了新的文献求助20
7秒前
任驰骋发布了新的文献求助10
8秒前
Dzinver发布了新的文献求助10
8秒前
naruto完成签到 ,获得积分10
9秒前
明前易拉罐完成签到,获得积分10
10秒前
沉默笑蓝发布了新的文献求助10
10秒前
大个的应助被Felix采纳,获得10
10秒前
10秒前
11秒前
烹全鱼宴发布了新的文献求助10
11秒前
尊敬鸿完成签到,获得积分10
13秒前
康轩铭完成签到 ,获得积分10
13秒前
长青完成签到 ,获得积分10
14秒前
Yoopakho完成签到,获得积分10
14秒前
14秒前
Aoooo完成签到,获得积分10
14秒前
FashionBoy的应助被Sean采纳,获得10
15秒前
Dzinver完成签到,获得积分10
15秒前
15秒前
优雅的夏旋完成签到,获得积分10
15秒前
李健的应助被村口烫头祁师傅采纳,获得10
15秒前
任驰骋完成签到,获得积分10
16秒前
xiedi的应助被liu采纳,获得10
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181823
求助须知:如何正确求助?哪些是违规求助? 9571511
关于积分的说明 21818391
捐赠科研通 7778076
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479614